IRVINE, Calif., Jan. 18 /PRNewswire/ -- Relsys International, the leading provider of software solutions for Drug Safety and Risk Management, announced six new customers for its flagship Argus Safety(TM) product. These new customer wins, along with expanded relationships with a number of current customers, extend the company's leadership in the global pharmaceutical industry, where Argus is the most widely used commercially available drug safety solution.
"Twenty years ago, we founded the company with a vision of working with the leading pharmaceutical companies to develop drug safety solutions that met their needs, and would revolutionize the way the industry managed this critical function," said Dave Bajaj, President and CEO of Relsys International. "It's humbling and gratifying that as we celebrate our 20th anniversary, we are acknowledged as the industry leader, and have seen our products grow to meet the regulatory reporting and pharmacovigilance needs of pharmaceutical companies around the world."
Argus Safety has replaced other commercial products in all six of the contracts announced by Relsys. Among these are Pfizer, the world's largest pharmaceutical company, where Argus replaced a competitive COTS product, Otuska Pharmaceuticals and Solvay. Other new contracts included Pronova AS, Relsys' first Norwegian client, Sciclone Pharmaceuticals, a growing biotechnology organization in the Bay Area of California, and Avexa, the company's first Australian client.
In addition to these new clients, the company announced continued growth with its existing client base through additional software and services contracts at clients such as Lilly, Novartis, Allergan, Shire, and Novo-Nordisk.
The company attributed its recent success to the release of the Argus Safety 4.2 suite. "Industry analysts and customers alike have praised the Argus 4.2 suite, saying it is significantly advancing the benchmark," noted Sanket Agrawal, Relsys' Chief Strategy Officer. "With each new product release and strategic customer win, Relsys is more strongly positioned to bring increased value to the industry through innovations in systematic benefit/risk management and healthcare integration."
In January, Relsys will be presenting upcoming innovations at the Annual Drug Safety & Pharmacovigilance Conference in Amsterdam and exhibiting its latest Pharmacovigilance offerings at DIA-PV& Risk Management in Washington DC.
About Relsys International
Relsys International provides a complete systems solution for pharmacovigilance and risk management that help pharmaceutical, biotech and medical device companies improve drug safety and ensure ongoing compliance with global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients' corporate risk management strategies. Argus Safety(TM), the company's flagship product, is the world's best selling drug safety software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit www.relsys.net, or call +1 949-453-1715 (in Europe call +44 20 8849 8058).
Relsys InternationalCONTACT: John Loucks of Relsys International, +1-949-453-1715,johnl@relsys.net; or Rick Sharga of CJ Patrick Company, +1-949-387-6402,rsharga@cjpatrickcompany.com, for Relsys International
Web site: http://www.relsys.net/
